Evolution of radiation therapy within the German Hodgkin study group trials

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 9, 2011, Pages 1073-1080

  Eich, Hans Theodor ^a,b   Kriz, Jan ^b   Müller, Rolf Peter ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Hodgkin lymphoma; Involved node radiotherapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CLINICAL EVALUATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GONADAL DAMAGE; HODGKIN DISEASE; HUMAN; LAPAROTOMY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; QUALITY CONTROL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TOXICITY; REVIEW; SECOND CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80053014447     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0088     Document Type: Review

References (28)

1. Diehl V, Josting A, eds. 25 Years German Hodgkin Study Group. Germany: Medizin & Wissen; 2004.
2. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early stage unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608. (Pubitemid 46594052)
3. Engert A, Pluetschow A, Eich HT, et al. Reduced treatment intensity in patients with early stage Hodgkin's Lymphoma. N Engl J Med 2010;363:640-652.
4. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395. (Pubitemid 36682817)
5. Duehmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905-2914. (Pubitemid 32538201)
6. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomised clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985;11:5-22. (Pubitemid 15169347)
7. Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988;6:1576-1583. (Pubitemid 19092393)
8. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-3135. (Pubitemid 46638951)
9. Shore T, Nelson N, Weinerman B. A metaanalysis of stages II Hodgkin' disease. Cancer 1990;65:1155-1160.
10. Wasserman TH, Trenker DA, Fineberg B, Kucik N. Cure of early stage Hodgkin's disease with subtotal nodal irradiation. Cancer 1991;68:1208-1215.
11. Engert A, Franklin J, Eich HT, et al. Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early-favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;10;25:3495-3502. (Pubitemid 47310889)
12. Specht L, Gray ML, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomised trials involving 3,888 patients. J Clin Oncol 1998;16:830-843. (Pubitemid 28108714)
13. Hagenbeek A, Carde P, Noordijk E, et al. Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomised phase III clinical trial in 762 patients (H7 study) [abstract]. Blood 1997;90(Suppl 1):Abstract 2603.
14. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favourable Hodgkin's disease. J Clin Oncol 1988;6:1822-1831. (Pubitemid 19089064)
15. Radford JA, Cowan RA, Ryder WD. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS) IA/IIA Hodgkin's disease. Results of a randomised pilot study [abstract]. Ann Oncol 1996;7:Abstract 66.
16. Eich HT, Staar S, Gossmann A, et al. Centralized radiation oncological review of cross-sectional imaging of Hodgkin's disease leads to significant changes of the required involved field - results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biopl Phys 2004;58:1120-1126.
17. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978;42:1039-1045. (Pubitemid 9054556)
18. Eich HT, Engenhart-Cabillic R, Hansemann K, et al. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma - an analysis of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2008;71:1419-1424.
19. Borchman P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial [abstract]. Haematologica 2010;95(Suppl):Abstract 1146
20. Klimm B, Eich HT, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 2007;18:357-363. (Pubitemid 46323106)
21. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early favourable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-4206.
22. rd Annual Meeting and Exposition of the American Society of Hematology; December 10-13, 2011; Orlando, Florida. Abstract 765.
23. Eich HT, Mueller RP, Engenhart-Cabillic R, et al. Involved node radiotherapy in early-stage Hodgkin's lymphoma - definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008;184:406-410.
24. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306. (Pubitemid 16028022)
25. Aleman BMP, Raemaekers J, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-2406. (Pubitemid 36682818)
26. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-4554.
27. Eich HT, Gosmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's Lymphoma-analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group. Int J Radiat Oncol Biopl Phys 2007;69:1187-1192. (Pubitemid 47625831)
28. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989-3994.